Ananda Pharma’s ACTiON Trial Enters Phase 2… | Cannabivo
Ananda Pharma’s ACTiON Trial Enters Phase 2 After First UK Patient Dose
Ananda Pharma has dosed the first patient in the UK’s NIHR-backed ACTiON Phase 2 trial testing CBD-based MRX1 for chemotherapy-induced neuropathy.
ACTiON is a UK Phase 2 study evaluating Ananda Pharma’s proprietary CBD-based oral solution MRX1 as a treatment for chemotherapy-induced peripheral neuropathy.
The study is led by Professor Marie Fallon at the University of Edinburgh in Scotland.
The ACTiON study received an Efficacy and Mechanism Evaluation grant from the UK’s NIHR. The grant is non-dilutive and involves independent scientific scrutiny before approval.
The supplied facts do not report an efficacy result. An earlier Phase 1 pharmacokinetic trial found a clean safety profile across 20 participants, supporting progression to Phase 2.
ENDOCAN is a parallel Phase 2 study evaluating MRX1 for endometriosis-associated pain.
Cannabis club directory and information resource for social clubs in Europe.